SM 10906
Alternative Names: SM-10906Latest Information Update: 30 Aug 2007
Price :
$50 *
At a glance
- Originator Sumitomo Pharmaceuticals
- Class Antiplatelets
- Mechanism of Action Collagenase stimulants; Platelet aggregation inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Blood coagulation disorders; Hypertrophic scars
Most Recent Events
- 07 Jan 2004 No development reported - Preclinical for Coagulation disorders in Japan (unspecified route)
- 28 Jun 2001 No-Development-Reported for Hypertrophic scars in Japan (Unknown route)
- 19 Jan 1998 Preclinical development for Hypertrophic scars in Japan (Unknown route)